We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Astrazeneca Plc | AZN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 16:35:23 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 12,092.00 | 12,010.00 | 12,178.00 | 12,050.00 | 12,156.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 07/4/2024 00:13 by philanderer AstraZeneca chief's huge payday provokes investor revolt despite stellar record at UK drugs giant |
Posted at 19/2/2024 15:03 by smcni1968 Hopefully the US investors will get this moving up tomorrow |
Posted at 08/2/2024 14:55 by philanderer ‘Many investors view AstraZeneca as invincible given its success in recent years, yet its latest results showed that even the mighty can disappoint. The drugs giant missed fourth quarter earnings expectations due to more money being spent on research and development and a greater contribution from lower-margin sales in emerging markets. However, the business remains optimistic about the prospects for its cancer and rare disease drugs,’ AJ Bell analyst Russ Mould commented. |
Posted at 15/12/2023 14:41 by philanderer Telegraph tipQuestor Wealth Preserver: as one of our holdings looks likely to be taken over, we are replacing it with a high-quality pharmaceutical stock Article: |
Posted at 12/7/2023 11:02 by smcni1968 AstraZeneca's recent de-rating is now an entry point for investors given base business growth, UBS analysts write in a research note. "Now that last week's press release has triggered a de-rating, we are of the view that investors can come back to the stock for the performance of in-market products and their net present value that already supports the valuation leaving meaningful pipeline optionality," the analysts say. Investors can gain access to a sector-leading pipeline and growth at a reasonable price, they say. UBS lifts it stock rating to buy from hold and price target to 13,000 pence from 12,500 pence. Shares are up 0.9% at 10,168.00 pence. |
Posted at 05/7/2023 10:06 by philanderer Berenberg lowers AstraZeneca target priceA lung cancer treatment from AstraZeneca (AZN) failed to meet high investor expectations but the share price drop is ‘overdone̵ Analyst Luisa Hector reiterated her ‘buy’ recommendation but lowered her target price slightly from £135 to £133 on the Citywire Elite Companies AAA-rated stock, which rose 2.2%, or 228p, to £106.02 on Tuesday. The pharmaceutical giant, along with its partner Daiichi Sankyo, announced positive progression-free survival headline data for their lung cancer treatment. ‘The absence of more positive language in the press release, such as “clinically meaningful”, and the occurrence of some fatal interstitial lung disease events missed high investor expectations, resulting in AstraZeneca’s share price falling by 8%,’ said Hector. She said the future of the drug relies on further testing, which is expected in the next six months. ‘We lower our price target to £133… a much smaller reduction than the share price move of 900p. We think the stock reaction is overdone given the overall strength of AstraZeneca’s pipeline,’ she said. citywire.com |
Posted at 03/7/2023 14:01 by philanderer AstraZeneca stock value falls by nearly £10bn after cancer drug trial resultsMarket value drops by 6% on concerns that new lung cancer drug may not be as successful as hoped Analysts at Citi greeted the results positively overall but said the drug “may not be the home run in absolute benefit that investors had hoped for” – . Some analysts have pinned $10bn (£8bn) to $18bn (£14bn) sales estimates on the new drug. Analysts at Barclays and Credit Suisse said shareholders had been looking for AstraZeneca to declare the results “clinically meaningful”. The company said clinical significance was a “subjective assessment” and further analysis was required to interpret the results. Analysts at Jefferies said the results seem ‘likely to fall short of best case’. |
Posted at 27/1/2023 16:44 by hopefuldave I’m not too bothered about covid as Astra have fantastic medicines for other diseases.As i newish investor from 118 down to 106,obviously I’m a bit concerned. I haven’t experienced such volatility before. Hopefully things will improve. Will they?. |
Posted at 06/10/2022 18:41 by 1knocker If there is a market fall AstraZ will fall along with everything else. I sold 20% of my holding at 114 ( I now wish I had been more decisive and sold more) and await a further dip before buying back in. The bond markets show how stressed the markets are. The odds look pretty strong on further falls to provide an opportunity to buy back before the month is out. I have a limit order in. I am happy to wait on the sidelines with cash in hand.This has been a depressing year for investors, but it has at least provided numerous opportunities to reduce the capital committed to core holdings while maintaining or even increasing the number of shares held, and with shares paying dividends half yearly there is not even much risk of dropping a dividend. |
Posted at 02/10/2022 11:33 by rech @ bostonbornIn Questor’s view, investors do not necessarily face a binary choice between safety and growth. Indeed, some companies, such as the FTSE 100 pharmaceutical company AstraZeneca, offer the best of both. From a defensive standpoint, its recent half-year results highlight its financial strength amid an uncertain global economic outlook. Revenue and core profits grew by 48pc and 44pc respectively and all business units delivered an improved performance. This led the company to raise its sales guidance for the full year: it now expects a percentage increase in the low 20s. A net‑debt‑ The company’s improving financial performance allows it to invest greater sums in research and development. Core R&D spending in the first half of the year increased by 40pc and as a proportion of sales it is now 1 percentage point higher at 23pc than in the same period of the previous year. This should strengthen its product pipeline in an era when rising healthcare spending creates significant long-term growth opportunities. The world’s population is rapidly growing and quickly ageing. Between now and 2050 the UN forecasts it to grow from eight billion people to 9.7 billion people. Over the same period the number of people aged 65 or over is expected to almost double to 1.6 billion. With 71pc of worldwide deaths caused by non-communicable diseases such as cancer, cardiovascular disease and others that cannot be transmitted between people, demand for AstraZeneca’s oncology and biopharmaceutical products is likely to rise. Last year’s acquisition of rare diseases specialist Alexion provides a further long-term growth opportunity. Currently, 400 million people are affected by a rare disease but only 5pc of the more than 7,000 rare diseases known to exist today have treatments. Separately, AstraZeneca’s large presence in emerging markets, which account for 28pc of its revenues, makes it well placed to capitalise on their growth potential. In fact, according to the IMF they will grow almost three times faster than developed markets next year. Of course, AstraZeneca is not immune from potential threats to its performance. Rumours persist that its chief executive, Pascal Soriot, is to leave in the near future. His eventual departure, after he led the company to a vast improvement in fortunes since he took over a decade ago, is almost certain to cause a degree of uncertainty, which is likely to be reflected in heightened share price volatility. Similarly, the company’s outperformance of the wider stock market means it trades on a relatively rich valuation. It has gained 35pc and beaten the FTSE 100 by 41 percentage points since this column first advised readers to buy the stock in August 2019. As a result it now trades at around 17 times forecast earnings. In Questor’s view, AstraZeneca is extremely worthy of its premium valuation. Its potent mix of defensive and growth characteristics is particularly attractive in the current economic environment. Its exposure to emerging markets, its focus on non-communicable diseases that are likely to become more prevalent and its growing R&D spending mean it should remain a mainstay of investors’ portfolios. Buy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
